Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infe...

Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are ophthalmic formulations that deliver a variety of therapeutic agents, including but not limited to rapamycin (sirolimus), analogs thereof (rapalogs) or other mTOR inhibitors, to a subject for an extended period of time. The ophth...

A therapeutic agent for glaucoma including a combination of pharmaceutically effective amounts of a Rho kinase inhibitor and a [beta]-blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the [beta]-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. A method of treating glaucoma including administering effective amounts of a Rho kinase inhibitor and a [beta]-blocker to a patient, wherein the Rho kina...

Disclosed are a method and dosage of eye drops containing 1.5% (w/v) of levofloxacin, characterized in that, when the eye drops are dropped into the eyes thrice a day, bacterial conjunctivitis can be healed within a short period of time, compared with the conventional case where 0.5% (w/v) eye drops are used thrice a day, without increasing the incidence of side effects. Healing of an eye infection within a short period of time contributes to shortening of the exposure time of a pathogenic bacte...

Disclosed is a novel prophylactic or therapeutic agent for chorioretinal diseases. Temsirolimus, everolimus and the like, which are sirolimus derivatives, exhibit an excellent anti-angiogenic activity in a retina and a choroid, and are therefore useful as therapeutic agents for chorioretinal diseases such as age-related macular degeneration.

The invention provides a novel prophylactic or therapeutic agent for a posterior ocular disease. Pramipexole which is a non-ergot selective D 2 receptor agonist or a salt thereof exhibits excellent inhibitory effect on neovascularization, suppressive effect on photoreceptor cell damage and suppressive effect on vascular hyperpermeability in a posterior ocular tissue such as choroid or retina, and is therefore useful as a prophylactic or therapeutic agent for a posterior ocular disease such as ag...

Disclosed is a novel prophylactic or therapeutic agent for a posterior ocular disease. Pramipexole (a non-ergot selective Dreceptor agonist) or a salt thereof has an excellent anti-angiogenic activity, an excellent activity of preventing photoreceptor cell dysfunction, and an excellent activity of enhancing vascular permeability in a posterior ocular tissue such as a choroid and a retina, and is therefore useful as a prophylactic or therapeutic agent for a posterior ocular disease such as age-re...

Disclosed is a novel use application of buformin, phenformin or a salt of buformin or phenformin for medical purposes. Buformin, phenformin or a salt of buformin or phenformin can exhibit an excellent anti-angiogenic activity in a choroid, and can also prevent the death of photoreceptor cells caused by light damage. Therefore, buformin, phenformin or a salt of buformin or phenformin is useful as a prophylactic or therapeutic agent for age-related macular degeneration.

Disclosed is a novel prophylactic or therapeutic agent for a posterior ocular disease. Ropinirole or a salt thereof has an excellent anti-angiogenic activity and an excellent inhibitory effect on elevated vascular permeability in a posterior ocular tissue such as a choroid or a retina, and is therefore useful as a prophylactic or therapeutic agent for a posterior ocular disease such as age-related macular degeneration, diabetic retinopathy and diabetic macular edema.

Disclosed is a novel prophylactic or therapeutic agent for a posterior ocular disease. Pramipexole (a non-ergot selective D2 receptor agonist) or a salt thereof has an excellent anti-angiogenic activity, an excellent activity of preventing photoreceptor cell dysfunction, and an excellent activity of enhancing vascular permeability in a posterior ocular tissue such as a choroid and a retina, and is therefore useful as a prophylactic or therapeutic agent for a posterior ocular disease such as age-...